Analysts

Analysts Pivotal Research initiated coverage on SpaceX (SPCX) with a buy rating and a $220 target price, indicating a potential upside of 48%

09/08/2026, 04:37 AM investing rating_growth Analysts: analysts aero_defense

Pivotal Research has initiated coverage of SpaceX with a buy rating, emphasizing that the company's $2 trillion valuation hinges on overcoming a significant engineering challenge related to the reusability of its Starship rockets.

Analysts UBS upgraded Lockheed Martin (LMT) to Buy and raised target price to $674 (upside +28%)

09/08/2026, 04:37 AM investing rating_growth Analysts: analysts, UBS defense finance Lockheed Martin

UBS has upgraded Lockheed Martin to a 'buy' rating, citing significant potential for earnings growth that the market has not yet recognized, with a new price target suggesting a 28% upside from current levels.

Stocks Making Significant Pre-Market Moves: Roivant Sciences Rallies 24%, Lockheed Martin Upgraded by UBS, Novartis Falls 12%, Peloton Downgraded by Morgan Stanley

09/08/2026, 04:37 AM business review Roivant Sciences Peloton Boston Scientific Novartis Lockheed Martin

Premarket trading saw significant movements in several companies, notably Roivant Sciences, which experienced a 24% surge following positive trial results, while Novartis faced a 12% drop due to disappointing drug trial outcomes.

Samsung and TSMC Commit to ASML’s Advanced Chipmaking Tools Amid Rising AI Demand

09/08/2026, 01:37 AM announcement semiconductors ai Taiwan Semiconductor Manufacturing Company ASML Samsung

Samsung and TSMC's commitment to ASML's High NA extreme ultraviolet lithography machines highlights the growing demand for advanced chip technology, particularly for AI applications, which could significantly impact ASML's future growth and market position.

Novartis Faces Setback in Cardiovascular Drug Trial, Impacting Market Outlook for Lp(a) Treatments

09/07/2026, 10:36 PM business review healthcare pharma Ionis Pharmaceuticals Amgen Novartis Eli Lilly

Novartis' recent failure in a key cardiovascular trial for its cholesterol drug pelacarsen has raised concerns about the viability of treatments targeting Lp(a), a cholesterol variant linked to increased heart disease risk, impacting not only Novartis but also its competitors Amgen and Eli Lilly.

HSBC Identifies Key Risks That Could Disrupt Global Market Resilience

09/07/2026, 09:36 PM research finance HSBC Holdings Deutsche Bank

HSBC identifies several key risks that could challenge the resilience of global markets, including higher corporate taxes and a potential shift in the relationship between stocks and bonds, particularly in the U.S. This analysis is crucial for investors as it highlights vulnerabilities that could impact market stability.

China’s Trade Surplus Grows as Exports Surge 25% in August Despite Weaker Import Demand

09/07/2026, 08:36 PM economy review

China's trade data for August reveals a significant increase in exports, while imports fell short of expectations, highlighting ongoing challenges in domestic demand and the need for trade rebalancing.

Oil Prices Rise for Third Consecutive Day Amid Escalating Mideast Tensions

09/07/2026, 06:36 PM forecast Analysts: Goldman Sachs energy

Oil prices have risen for three consecutive days, reaching six-week highs due to escalating tensions between the U.S. and Iran, which could lead to prolonged disruptions in oil supply.

China’s Declining Consumer Spending Raises Global Concerns

09/07/2026, 04:36 PM research finance

China's slowing consumer spending and declining disposable income are raising concerns globally, particularly regarding the impact on its economy and international trade dynamics. The situation is drawing scrutiny from G20 nations, highlighting the interconnectedness of China's domestic challenges and global economic stability.

Analysts UBS expect investors to buy equities and bonds ahead of potential Fed rate hike

09/07/2026, 05:36 AM forecast Analysts: analysts, UBS finance ai

UBS indicates that the unexpectedly strong U.S. jobs report has heightened the likelihood of a Federal Reserve interest rate hike in September, presenting investors with strategic opportunities in equities, bonds, and gold.